Leerink Partners is the famous Corporate Investor, which was founded in 1995. The venture was found in North America in United States. The main department of described Corporate Investor is located in the Boston.
The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight TESARO, AlloVir, Living Proof. We can highlight the next thriving fund investment areas, such as Medical, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The overall number of key employees were 1.
The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the Leerink Partners, startups are often financed by Atlas Venture, Omega Funds, The Column Group. The meaningful sponsors for the fund in investment in the same round are Foresite Capital, Fidelity Management and Research Company, Cormorant Asset Management. In the next rounds fund is usually obtained by The Baupost Group, Omega Funds, North Bridge Venture Partners & Growth Equity.
Considering the real fund results, this Corporate Investor is 13 percentage points less often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The higher amount of exits for fund were in 2018. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Leerink Partners performs on 31 percentage points more the average number of lead investments. The fund is constantly included in less than 2 deals per year.
Related Funds
Fund Name | Location |
Avanade | Seattle, United States, Washington |
B3Forin | - |
Brava Investments | New York, New York, United States |
Caretech Pte Inc | Central, Central Region, Singapore |
Crocker Mountain Capital | - |
Epic Games | Cary, North Carolina, United States |
Furman Selz Inc | New York, New York, United States |
Heartland Payment Systems | New Jersey, Princeton, United States |
Innov8on | Mazowieckie, Poland, Warsaw |
Khaleeji Commercial Bank | Bahrain, Capital Governorate, Manama |
Loomis AB | Stockholm, Stockholm County, Sweden |
New Vantage Group | Mclean, United States, Virginia |
Raga Partners | New York, New York, United States |
RFW Banro Investments | - |
Senmed Medical Ventures | - |
Shaka Ventures | Kenya, Nairobi, Nairobi Area |
ShareLink Capital | China, Shanghai |
Skayle | Central, Central Region, Singapore |
Weiji Investment | China, Guangdong, Shenzhen |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Odyssey Therapeutics | $101M | 05 Dec 2023 | Cambridge, Massachusetts, United States | ||
Kinnate Biopharma | $98M | 26 Aug 2020 | San Diego, California, United States | ||
AlloVir | $120M | 23 May 2019 | Houston, Texas, United States | ||
Fulcrum Therapeutics | $80M | 05 Sep 2018 | Cambridge, Massachusetts, United States | ||
Precision BioSciences | $110M | 08 Jun 2018 | Durham, North Carolina, United States | ||
Fog Pharmaceuticals | $66M | 16 May 2018 | Cambridge, Massachusetts, United States | ||
Generation Bio | $100M | 27 Feb 2018 | Cambridge, Massachusetts, United States | ||
Avrobio | $60M | 01 Feb 2018 | Cambridge, Massachusetts, United States | ||
Arcus Biosciences | $107M | 13 Nov 2017 | Hayward, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Odyssey Therapeutics | $101M | 05 Dec 2023 | Cambridge, Massachusetts, United States | ||
Kinnate Biopharma | $98M | 26 Aug 2020 | San Diego, California, United States | ||
AlloVir | $120M | 23 May 2019 | Houston, Texas, United States | ||
Fulcrum Therapeutics | $80M | 05 Sep 2018 | Cambridge, Massachusetts, United States | ||
Precision BioSciences | $110M | 08 Jun 2018 | Durham, North Carolina, United States | ||
Fog Pharmaceuticals | $66M | 16 May 2018 | Cambridge, Massachusetts, United States | ||
Generation Bio | $100M | 27 Feb 2018 | Cambridge, Massachusetts, United States | ||
Avrobio | $60M | 01 Feb 2018 | Cambridge, Massachusetts, United States | ||
Arcus Biosciences | $107M | 13 Nov 2017 | Hayward, California, United States |